Synthesis of 1-hydroxy-3-O-substituted xanthone derivatives and their structure-activity relationship on acetylcholinesterase inhibitory effect

References

• Alawi MS, Awad TA, Mohamed MA, Khalid A, Ismail EMO, Alfatih F, Naz S, Ul-Haq Z. 2020. Insights into the molecular basis of acetylcholinesterase inhibition by xanthones: an integrative in silico and in vitro approach. Mol Simul. 46(4):253–261.
   Web of Science ®Google Scholar
• Alzheimer’s Association. 2020. Alzheimer’s disease facts and figures. Alzheimers Dement. 16(3):391–460.
   Web of Science ®Google Scholar
• Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M, Andrisano V, Cavalli A, Recanatini M, Valenti P. 2005. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem. 48(13):4444–4456.
   PubMed Web of Science ®Google Scholar
• Birks JS, Harvey RJ. 2018. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 6(6):CD001190.
   PubMedGoogle Scholar
• Blackard WG, Jr., Sood GK, Crowe DR, Fallon MB. 1998. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol. 26(1):57–59.
   PubMed Web of Science ®Google Scholar
• Chi XQ, Hou B, Yang L, Zi CT, Lv YF, Li JY, Ren FC, Yuan MY, Hu JM, Zhou J. 2020. Design, synthesis and cholinesterase inhibitory activity of alpha-mangostin derivatives. Nat Prod Res. 34(10):1380–1388.
   PubMed Web of Science ®Google Scholar
• Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. 2013. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 11(3):315–335.
   PubMed Web of Science ®Google Scholar
• Craig LA, Hong NS, McDonald RJ. 2011. Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neurosci Biobehav Rev. 35(6):1397–1409.
   PubMed Web of Science ®Google Scholar
• Crismon ML. 1994. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 28(6):744–751.
   PubMed Web of Science ®Google Scholar
• Eaton PE, Carlson GR, Lee JT. 1973. Phosphorus pentoxide-methanesulfonic acid. Convenient alternative to polyphosphoric acid. J Org Chem. 38(23):4071–4073.
   Web of Science ®Google Scholar
• Ee G, Teh SS, Mah SH, Jamaluddin N, Sahimi M, Ahmad Z. 2015. Acetyl-cholinesterase enzyme inhibitory effect of Calophyllum species. Trop J Pharm Res. 14(11):2005.
   Web of Science ®Google Scholar
• Ellman GL, Courtney K, Andres V, Featherstone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7(2):88–95.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7(2):88–95.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, Deuschl G, Parmar P, Brainin M, Murray C. 2020. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 19(3):255–265.
   PubMed Web of Science ®Google Scholar
• Frahm AW, Chaudhuri RK. 1979. 13 C NMR spectroscopy of substituted xanthones—II: 13C NMR spectral study of polyhydroxy xanthones. Tetrahedron. 35(17):2035–2038.
   Web of Science ®Google Scholar
• Freitas VLS, Ribeiro da Silva M. 2018. Influence of hydroxyl functional group on the structure and stability of xanthone: a computational approach. Molecules. 23(11):2962.
   PubMed Web of Science ®Google Scholar
• Grossberg S. 2017. Acetylcholine neuromodulation in normal and abnormal learning and memory: vigilance control in waking, sleep, autism, amnesia and Alzheimer’s disease. Front Neural Circuits. 11:82.
   PubMed Web of Science ®Google Scholar
• Grover PK, Shah GD, Shah RC. 1955. Xanthones. Part IV. A new synthesis of hydroxyxanthones and hydroxybenzophenones. J Chem Soc.1955(0):3982–3985.
   Web of Science ®Google Scholar
• Gunter NV, Teh SS, Lim YM, Mah SH. 2020. Natural xanthones and skin inflammatory diseases: multitargeting mechanisms of action and potential application. Front Pharmacol. 11(1873):594202.
   PubMedGoogle Scholar
• Guo N, Liu J, Qin L, Jiang D, You X, Lu K, Teng Y-O, Yu P. 2015. Synthesis and antitumor activity evaluation of a novel series of xanthone derivatives. J Asian Nat Prod Res. 17(4):377–383.
   PubMed Web of Science ®Google Scholar
• Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. 2020. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 19(2):147–157.
   PubMed Web of Science ®Google Scholar
• Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur OA, Jessen F, Fliessbach K, Neumaier B, Fink GR, et al. 2018. Networks of tau distribution in Alzheimer’s disease. Brain. 141(2):568–581.
   PubMedGoogle Scholar
• Jang C, Yadav DK, Subedi L, Venkatesan R, Venkanna A, Afzal S, Lee E, Yoo J, Ji E, Kim SY, et al. 2018. Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay. Sci Rep. 8(1):14921.
   PubMedGoogle Scholar
• Kwong HC, Mah SH, Chia TS, Quah CK, Lim GK, Kumar CSC. 2017. Cholinesterase inhibitory activities of adamantyl-based derivatives and their molecular docking studies. Molecules. 22(6):1005.
   PubMed Web of Science ®Google Scholar
• Loh ZH, Kwong HC, Lam KW, Teh SS, Ee GCL, Quah CK, Ho ASH, Mah SH. 2021. New 3-O-substituted xanthone derivatives as promising acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem. 36(1):627–639.
   PubMed Web of Science ®Google Scholar
• Lou YH, Wang JS, Dong G, Guo PP, Wei DD, Xie S, Yang MH, Kong LY. 2015. The acute hepatotoxicity of tacrine explained by 1H NMR based metabolomic profiling. Toxicol Res. 4(6):1465–1478.
   Web of Science ®Google Scholar
• Luo L, Li Y, Qiang X, Cao Z, Xu R, Yang X, Xiao G, Song Q, Tan Z, Deng Y. 2017. Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease. Bioorg Med Chem. 25(6):1997–2009.
   PubMed Web of Science ®Google Scholar
• Menendez CA, Biscussi B, Accordino S, Paula Murray A, Gerbino DC, Appignanesi GA. 2017. Design, synthesis and biological evaluation of 1,3-dihydroxyxanthone derivatives: effective agents against acetylcholinesterase. Bioorg Chem. 75(5):201–209.
   PubMedGoogle Scholar
• Nag G, Das S, Das S, Mandal S, De B. 2015. Antioxidant, anti-acetylcholinesterase and antiglycosidase properties of three species of Swertia, their xanthones and amarogentin: a comparative study. Phcog J. 7(2):117–123.
   PubMedGoogle Scholar
• Narasimhan S, Maheshwaran S, Abu-Yousef IA, Majdalawieh AF, Rethavathi J, Das PE, Poltronieri P. 2017. Anti-bacterial and anti-fungal activity of xanthones obtained via semisynthetic modification of α-mangostin from Garcinia mangostana. Molecules. 22(2):275–288.
   PubMed Web of Science ®Google Scholar
• Qin J, Lan W, Liu Z, Huang J, Tang H, Wang H. 2013. Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents. Chem Cent J. 7(1):78.
   PubMedGoogle Scholar
• Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, Andrisano V, Cavrini V, Cavalli A, Recanatini M, et al. 2001. Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives. J Med Chem. 44(23):3810–3820.
   PubMed Web of Science ®Google Scholar
• Saenkham A, Jaratrungtawee A, Siriwattanasathien Y, Boonsri P, Chainok K, Suksamrarn A, Namsa-aid M, Pattanaprateeb P, Suksamrarn S. 2020. Highly potent cholinesterase inhibition of geranylated xanthones from Garcinia fusca and molecular docking studies. Fitoterapia. 146:104637.
   PubMed Web of Science ®Google Scholar
• Seca AM, Leal SB, Pinto DC, Barreto MC, Silva AM. 2014. Xanthenedione derivatives, new promising antioxidant and acetylcholinesterase inhibitor agents. Molecules. 19(6):8317–8333.
   PubMed Web of Science ®Google Scholar
• Svobodova B, Mezeiova E, Hepnarova V, Hrabinova M, Muckova L, Kobrlova T, Jun D, Soukup O, Jimeno ML, Marco-Contelles J, et al. 2019. Exploring structure-activity relationship in tacrine-squaramide derivatives as potent cholinesterase inhibitors. Biomolecules. 9(8):379.
   PubMed Web of Science ®Google Scholar
• Syahri J, Yuanita E, Achromi B, Wathon M, Syafri R, Armunanto R, Bambang P. 2017. Xanthone as antimalarial: QSAR analysis, synthesis, molecular docking and in-vitro antimalarial evaluation. Orient J Chem. 33(1):29–40.
   Web of Science ®Google Scholar
• Teh SS, Ee GCL, Mah SH, Ahmad Z. 2016. Structure–activity relationship study of secondary metabolites from Mesua beccariana, Mesua ferrea and Mesua congestiflora for anticholinesterase activity. Med Chem Res. 25(5):819–823.
   Web of Science ®Google Scholar
• Thongchai K, Anan A, Wanchalerm U, Yamaratee J, Sunit S. 2014. Synthesis of hydroxyxanthones and evaluations for their acetylcholinesterase inhibitory and neurotoxicity activities. KKU Sci J. 42(1):212–220.
   Google Scholar
• Vanessa VV, Mah SH. 2021. Xanthone: Potential acetylcholinesterase inhibitor for alzheimer’s disease treatment. Mini Rev Med Chem. 21(17):2521–2543.
   Web of Science ®Google Scholar